Molecular Data

Molecular Data ROE

Delisted

The Return on Equity (ROE) of Molecular Data (MKD) as of Oct 29, 2026 is 1,174.44 %. In the previous year, Return on Equity (ROE) was 89.40 % — a change of 1,213.69% (higher).

ROE

1,174.44 %

YoY

1,213.69%

Last updated:

In 2020, Molecular Data's return on equity (ROE) was 1,174.44 %, a 1,213.69% increase from the 89.40 % ROE in the previous year.

The Molecular Data ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
-1,826.93 CNY
Jan 1, 2018
413.21 CNY
Jan 1, 2019
89.40 CNY
Jan 1, 2020
1,174.44 CNY
The Molecular Data ROE history
YEARROEYoY
1,174.44 %+1,213.69%
89.40 %-78.36%
413.21 %-122.62%
-1,826.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Molecular Data Stock analysis

What does Molecular Data do? Molecular Data Inc. is a leading technology company specializing in the use of big data, artificial intelligence (AI), and blockchain technology in the chemical and pharmaceutical industry. The company was founded in 2014 and is headquartered in Shanghai, China. Molecular Data Inc. has a comprehensive database consisting of millions of chemical compounds, which aids chemists, pharmaceutical companies, and researchers in identifying, exploring, and developing new drugs. The company places great importance on integrating data and technologies to accelerate and improve drug development. Molecular Data Inc. provides cloud-based solutions based on the analysis of big data through AI algorithms and blockchain technology. It offers platforms, as well as consulting and training services, to support customers in efficiently utilizing the platforms. The company's main products include the MDL platform, which enables the integration of data, knowledge, and algorithms to accelerate drug development processes. The MDL platform is a cloud-based system that provides access to a database of millions of compounds and allows users to receive real-time results. Molecular Data Inc. also offers a blockchain-based platform for the chemical and pharmaceutical industry, enhancing the transparency and security of data and information. The platform facilitates secure data exchange between different companies and regulatory authorities, providing improved control and monitoring of data. Another important service provided by Molecular Data Inc. is consulting and training for companies in implementing big data, AI, and blockchain into their workflows. The company aims to equip its customers with the necessary skills and knowledge to optimize their business processes and increase competitiveness. Molecular Data Inc. is divided into several divisions to ensure efficient collaboration and product development. These divisions include research and development, sales and marketing, finance and administration, and information technology. The company strives to expand its business through strategic partnerships and acquisitions. It has already completed several acquisitions to strengthen its expertise in big data, AI, and blockchain. Through these strategic measures, the company has been able to offer its customers a comprehensive range of products and services to enhance performance and increase competitiveness. Overall, Molecular Data Inc. is a significant company in the chemical and pharmaceutical industry that specializes in the integration of data and technologies to enhance process efficiency and speed. The company aims to strengthen its position as a market leader through innovation and strategic partnerships. Molecular Data is one of the most popular companies on Eulerpool.

ROE Details

Decoding Molecular Data's Return on Equity (ROE)

Molecular Data's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Molecular Data's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Molecular Data's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Molecular Data’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Molecular Data stock

Return on Equity (ROE) of Molecular Data is 1,174.44 % in 2020.

Return on Equity (ROE) of Molecular Data changed from 89.40 % to 1,174.44 %, representing a 1,213.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Molecular Data since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Molecular Data with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Molecular Data

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Molecular Data